Clinical trials: Adebrelimab, open to volunteers
Small Cell Lung Cancer Extensive Stage
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
This study is a prospective, randomized, parallel, multicenter phase II study aimed at evaluating the efficacy and safety of irinotecan liposome (II) or etoposide combined with adebrelimab and carboplatin as first-line treatment…
- Trial name
- NCT06739928
- Testing
- Irinotecan liposome (II) combined with adebrelimab and carboplatin, etoposide combined with adebrelimab and carboplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Pancreatic Cancer
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
To evaluate the safety and efficacy of HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- Trial name
- NCT07131514
- Testing
- HRS-4642+AG +Adebrelimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Esophageal Squamous Cell Carcinoma, Immunotherapy
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers
- Trial name
- RICE (NCT06510660)
- Testing
- adebrelimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fujian Medical University Union Hospital
HR Positive/HER2 Low Breast Cancer
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
This is an open-label, phase II study evaluating the efficacy and safety of SHR-A1811 alone or in combination with Adebrelimab in Stage II-III HR Positive/HER2 Low Breast Cancer.
- Trial name
- NCT06340230
- Testing
- SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Shengjing Hospital
Non Small Cell Lung Cancer
Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
This is a prospective, single-arm study to investigate the efficacy and safety of Adebrelimab in combination with paclitaxel for injection (albumin bound) and platinum chemotherapy as neoadjuvant therapy in resectable non-small…
- Trial name
- NCT06299371
- Testing
- Adebrelimab, paclitaxel for injection (albumin bound), Cisplatin or Carboplatin
- Volunteers
- 36 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Esophageal Squamous Cell Carcinoma
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
This is a domestic exploratory, single-arm clinical study enrolling patients with histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma (ESCC), aiming to evaluate the efficacy and safety of…
- Trial name
- NCT07437898
- Testing
- Adebrelimab, chemotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The Affiliated Hospital of Putian University
Hepatocellular Carcinoma
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
- Trial name
- NCT07691762
- Testing
- SHR-8068 + Adebrelimab + Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 690 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
- Trial name
- ANCRE (NCT07595770)
- Testing
- • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Carcinoma, Non-Small-Cell Lung
A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This is a trial to evaluate the efficacy, safety, and tolerability of HS-10370 in combination with Platinum-based Doublet Chemotherapy With or Without Adebrelimab Versus Tislelizumab Plus Platinum-based Doublet Chemotherapy as…
- Trial name
- NCT07822542
- Testing
- HS-10370, Adebrelimab, Cisplatin
- Volunteers
- 448 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Resectable Esophageal Squamous Cell Carcinoma
Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Evaluating the efficacy and safety of PD-L1 (Programmed Death-L1)antibody combined with endoscopy and radiotherapy for inoperable cT1b-2 (clinical stage tumor 1b-2) esophageal squamous cell carcinoma
- Trial name
- NCT06599775
- Testing
- Adebrelimab injection, Albumin-Bound Paclitaxel, Carboplatin injection
- Volunteers
- 42 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Biliary Tract Carcinoma
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
This study will investigate the safety and effectiveness of a new combination treatment for patients with advanced bile duct cancer.
- Trial name
- NCT07392541
- Testing
- Adebrelimab, Gemcitabine + Cisplatin, Simvastatin 20mg
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tongji Hospital
Non-Small Cell Lung Cancer, Adebrelimab
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
To evaluate the major pathological response rate of Adibelimab combined with Apatinib neoadjuvant therapy in resectable non-small cell lung cancer.
- Conditions
- Non-Small Cell Lung Cancer, Adebrelimab, Apatinib
- Trial name
- NCT07031154
- Testing
- Adebrelimab, Apatinib
- Where
- China
- Volunteers
- 43 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
This is an open-label, randomized, multi-cohort, multi-center, phase Ib/II study to evaluate the safety and efficacy of Adebrelimab plus Irinotecan Liposome (II) with or without Famitinib in patients with extensive-stage small…
- Trial name
- NCT06332950
- Testing
- Adebrelimab, Irinotecan Liposome (II), Adebrelimab, Irinotecan Liposome (II), Famitinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Baohui Han
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Adebrelimab and Chemoradiotherapy in High-risk LANPC
This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).
- Trial name
- NCT06349889
- Testing
- Adebrelimab
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence
Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.
- Trial name
- NCT06280508
- Testing
- Adebrelimab, Apatinib, Gemcitabine, cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Advanced or Metastatic Esophageal Cancer
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer.
- Trial name
- NCT06474468
- Testing
- SHR-A2102；Adebrelimab；Cisplatin
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Glioblastoma
Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma
This is a prospective, randomized, open-label, multicenter phase II study. Newly-diagnosed primary glioblastoma patients who have undergone maximal safe resection or biopsy and completed standard concurrent chemoradiotherapy will…
- Trial name
- NCT07789379
- Testing
- Adebrelimab, Temozolomide, Procedure:Hyperbaric Oxygen Therapy
- Volunteers
- 94 people
- Sponsor
- Wei Jiang
Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma
This trial evaluated the efficacy of two adjuvant regimens following identical induction and concurrent chemoradiotherapy (IC+CCRT) in locoregionally advanced nasopharyngeal carcinoma (LANPC) patients with persistent EBV DNA…
- Trial name
- NCT07238569
- Testing
- Adebrelimab (PD-L1 inhibitor), Cisplatin (100mg/m2), Intensity-modulated radiotherapy
- Volunteers
- 516 people
- Sponsor
- Sun Yat-sen University
Pancreatic Ductal Adenocarcinoma (PDAC)
Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
This study intends to explore conversion therapy for locally advanced pancreatic cancer (LAPC). The intervention starts with modified stereotactic body radiation therapy (3-day regimen), followed by systemic therapy within 1-2…
- Trial name
- NCT07827053
- Testing
- Adebrelimab (PD-L1 inhibitor), NALIRIFOX, SBRT
- Volunteers
- 36 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Small Cell Lung Cancer (SCLC)
Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
This is a prospective multicenter, open-label, Phase I clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of propranolol hydrochloride in combination with adebrelimab and platinum-based…
- Trial name
- BRIO-SCLC (NCT07886047)
- Testing
- Propranolol Hydrochloride, Adebrelimab, Chemotherapy
- Where
- 4 sites in China
- Volunteers
- 18 people
- Sponsor
- Second Xiangya Hospital of Central South University